| Motexafin lutetium | |
|---|---|
|
Other names
Antrin; Lu texaphyrin; Lu-Tex; Lutetium texaphyrin; Lutrin; Optrin; PCI 0123 |
|
| Identifiers | |
| CAS number | 246252-04-0 |
| PubChem | 3081907 |
| Jmol-3D images | Image 1 |
|
|
| Properties | |
| Molecular formula | C52H72LuN5O14 |
| Molar mass | 1166.12 g mol−1 |
| (verify) (what is: /?) Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) |
|
| Infobox references | |
Motexafin lutetium is a texaphyrin, marketed as Antrin by Pharmacyclics Inc.
It is a photosensitiser for use in photodynamic therapy to treat skin conditions and superficial cancers.
It has also been tested for use in photoangioplasty (photodynamic treatment of diseased arteries).[1]
It is photoactivated by 732 nm light which allows greater depth of penetration.[2]
Phase II clinical trials were in progress in 1999.[3]
A phase I trial for prostate cancer reported in 2009.[4]
|
|||||